KDM6A and cancer: The promise for the use of small molecular inhibitors to target UTX/KDM6B and EZH2 enzymes as an anti-fibrotic therapy is provided by the FDA-approved EZH2 inhibitor, tazemetostat, an oral treatment currently being used with cancer patients (Eich et al., 2020; Straining and Eighmy, 2022; Zauderer et al., 2022).